Physician profile
Mitra Barahimi
NPI 1588907117
$13,156.21
in general payments reported to CMS, 2019-2025
8 companies · $726 in 2025
The $726 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $280 · 2021: $811 · 2022: $3,618 · 2023: $7,515 · 2024: $207 · 2025: $726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,265 · Food and Beverage: $1,174 · Travel and Lodging: $1,008.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,265.00 |
| Food and Beverage | $1,173.78 |
| Travel and Lodging | $1,008.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $7,870.69 | 2022-2024 | |
| Janssen Scientific Affairs, LLC | $1,653.16 | 2023-2024 | Tremfya, Stelara |
| Celgene Corporation | $1,275.82 | 2021-2024 | Zeposia |
| Abbvie INC. | $1,158.50 | 2019-2025 | Skyrizi |
| Janssen Biotech, INC. | $1,027.67 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $83.46 | 2023 | |
| Olympus America INC. | $55.36 | 2019 | |
| Boston Scientific Corporation | $31.55 | 2025 | Apollo Esg Nxt System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitra Barahimi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.